Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention

K P Morgan, A Kapur, K J Beatt

There are over 1.3 million known diabetic patients in the UK and a similar number who have the disease undiagnosed. Over 90% have non-insulin dependent diabetes mellitus usually characterised by insulin resistance and adult onset. Over half of all diabetic patients die of coronary disease and account for over a fifth of percutaneous coronary intervention (PCI) revascularisation procedures. Despite recent therapeutic advances such as new antiplatelet treatments and drug eluting stents, outcomes for diabetic patients after PCI are still significantly worse than for non-diabetic patients. This article summarises what is known about the pattern and severity of diabetic coronary disease, what mechanisms are responsible for these differences, and whether this information can help explain the poorer prognosis for these patients after PCI and form the basis of interventions to improve outcome.

There are over 1.3 million known diabetic patients in the UK and a similar number with the disease undiagnosed. Over 90% have non-insulin dependent diabetes mellitus (NIDDM), usually characterised by insulin resistance and adult onset. Over half of all diabetic patients die of coronary artery disease (CAD) and account for over a fifth of percutaneous coronary revascularisation procedures. Despite recent therapeutic advances such as new antiplatelet treatments and drug eluting stents, outcomes for diabetic patients after percutaneous coronary intervention (PCI) are still significantly worse than for non-diabetic patients. This article summarises what is known about the pattern and severity of diabetic CAD, what mechanisms are responsible for these differences, and whether this information can help explain the poorer prognosis for these patients after PCI and form the basis of interventions to improve outcome.

The introduction of intracoronary stenting in the late 1980s greatly changed the practice of angioplasty by reducing restenosis rates and improving outcome. Stenting was shown to be especially beneficial for diabetic patients.

The importance of platelet inhibition was realised early in the era of PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade, and EPISILNT (evaluation of platelet IIb/IIIa inhibitor for stenting) shows that abciximab decreased the one year mortality in diabetic patients from 4.5% to 2.5% and in non-diabetic patients from 2.6% to 1.9%.

Studies examining optimal PCI with drug eluting stents and glycoprotein IIb/IIIa inhibitors are encouraging. Increased benefit was seen again in the diabetic subgroup with relative rates of target lesion revascularisation reduced by about 70%.

The evolution in PCI technology has led to a reassessment of its role in the revascularisation of diabetic patients with multivessel disease. Large scale studies have shown that for patients with multivessel disease, although restenosis rates are higher among patients undergoing PCI than among those undergoing coronary artery bypass grafting (CABG), mortality rates are equal. However, diabetic subgroup analysis has led to the conclusion that PCI is inferior to CABG in these patients. It is difficult to extrapolate this conclusion to present day practice, as many of these trials were in the pre-stent era and all examined the diabetic group retrospectively. The CARDia (coronary artery revascularisation in diabetics) trial currently recruiting will answer whether optimal PCI is not inferior to up to date CABG in diabetic patients.

PATHOPHYSIOLOGY OF DIABETES MELLITUS

Insulin resistance is the first detectable abnormality found among patients who develop NIDDM and is associated with increased cardiovascular risk. Hyperinsulinaemia and hyperglycaemia are both important in promoting insulin resistance. In the absence of adequate insulin, fatty acids enter the liver and are oxidised, leading to hepatic gluconeogenesis and fatty acid oxidation, which contribute to lipid deposition in the coronary arteries and to the metabolic syndrome. Increased lipolysis and release of free fatty acids from adipose tissue to lipid-sensitive muscle and liver are the main factors underlying insulin resistance. In addition, the increased levels of free fatty acids and reduced levels of high density lipoprotein cholesterol that occur in diabetes lead to further lipid abnormalities, oxidative stress, inflammation and endothelial dysfunction.

The contribution of cholesterol was highlighted in the Framingham study, which showed a stronger association of serum cholesterol levels with CHD in diabetes than in non-diabetes. At the CHD-UKPDS trial, treatment with statins reduced the risk of cardiovascular events by 23% in diabetic patients.
and pre-dates the onset of overt hyperglycaemia by several years. It is implicated in the pathogenesis of a number of disorders that all have in common the same final effect of hyperinsulinaemia, low grade inflammation, and metabolic dysfunction. These disorders are collectively called the insulin resistance or metabolic syndrome and include abdominal obesity, increased triglyceride concentrations, decreased high density lipoprotein concentrations, raised blood pressure, and increased plasma glucose concentration.

As insulin resistance increases and pancreatic β cell function declines, NIDDM ensues.

**PATHOPHYSIOLOGY OF CAD IN NIDDM**

An association between diabetes mellitus (DM) and angina pectoris was first described in 1883 and shortly after it was hypothesised that the association was due to atherosclerosis. Much progress has been made in understanding the mechanisms underlying these observations (fig 1).

**Insulin resistance**

Hyperinsulinaemia, the biochemical hallmark of insulin resistance, is independently associated with an increased incidence of CAD. Additionally, the insulin resistance syndrome is associated with increased coronary risk. Insulin receptors are found on endothelial cells of both large and small blood vessels. They are thought to mediate glucose homoeostasis and control of vascular tone. Insulin has been shown to effect the secretion of the potent vasoconstrictors vascular endothelial growth factor and endothelin 1. Insulin also acts as a vasodilator in skeletal muscle through secretion of endothelial nitric oxide synthase. Interestingly this effect is impaired in insulin resistance.

**Endothelial dysfunction**

Endothelial dysfunction is defined as an imbalance where vasoconstriction outweighs the vasodilatory properties of the endothelium. Impaired vasodilatation is associated with increased cardiovascular risk and is apparent in patients with insulin resistance even before the development of overt hyperglycaemia.

**Hyperglycaemia**

Prolonged hyperglycaemia results in non-enzymatic glycosylation of proteins and lipids, oxidative stress, and protein kinase C activation, which is implicated in the development of coronary atherosclerosis. These pathways are complex and interlinked and their end effects are often irreversible.

**Dyslipidaemia**

Insulin resistance and NIDDM are associated with decreased high density lipoprotein and increased synthesis of the highly atherogenic low density lipoprotein particle. In the presence of hyperglycaemia this lipoprotein becomes glycosylated and is poorly recognised by the low density lipoprotein receptor. It is scavenged by tissue macrophages creating the foam cell, a constituent of the atherosclerotic plaque.

**Inflammation**

Vascular inflammation is important in the development of atherosclerosis and in determining plaque stability. Insulin resistance and DM are associated with upregulation of systemic acute phase reactants including C reactive protein. Increased serum C reactive protein concentration is associated with adverse cardiac outcomes. Circulating leucocytes are recruited at atherosclerotic sites by adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1). During endothelial activation the soluble form of VCAM-1 is shed into the circulation and is found in higher concentrations in patients with NIDDM than in non-diabetic controls. Concentrations of soluble VCAM-1 are also independently associated with increased coronary risk in patients with NIDDM.

**Prothrombotic state**

Increased concentrations of von Willebrand factor, factor VII, factor VIII, and plasminogen activator inhibitor type 1 are all
associated with the diabetic state resulting in potentiation of the coagulation cascade and platelet activation.

**WHAT MECHANISMS UNDERLIE THE POORER OUTCOMES AFTER PCI?**

The higher rates of repeat revascularisation and mortality after PCI in diabetic patients are mediated by two processes: restenosis and disease progression. These processes are effected in part by the metabolic dysregulation resulting from chronic hyperglycaemia and insulin resistance.

**Disease progression**

DM is associated with platelet and endothelial dysfunction resulting in accelerated atherosclerosis and plaque instability. Atheromatous plaques from diabetic patients removed by coronary atherecomy have greater lipid deposits and numbers of phagocytes.24 Diabetic patients presenting with an acute coronary syndrome are more likely to have a larger culprit lesion with associated plaque ulceration and intracoronary thrombus.25 Endothelial dysfunction is thought to induce negative arterial remodelling in response to atherosclerosis resulting in a decrease in luminal size.

Restenosis after PCI

Restenosis is caused by neointimal proliferation by vascular smooth muscle cells as a consequence of endothelial damage after balloon inflation and stent placement. Rates of restenosis and mortality are significantly higher among diabetic patients after PCI.25

A recent study examining the angiographic characteristics of diabetic patients requiring repeat revascularisation after multivessel PCI found that, of 18 patients who required repeat revascularisation, nine had evidence of significant disease progression in addition to restenosis and three had evidence of disease progression only. Disease progression contributed to over half of the requirement for further revascularisation procedures.26

Studies at the molecular, cellular, and clinical levels all agree that diabetic CAD is more aggressive. Understanding these differences and devising treatment interventions based on these observations are key to improving outcomes after PCI in these patients. Do diabetic patients have particular patterns and severity of disease, which account for their poorer prognosis?

**PATTERN OF CAD IN DIABETIC PATIENTS**

**Vessel calibref**

Coronary artery calibre is associated with body mass index and tends to be smaller in women. A small study has also reported significantly smaller sized vessels in 13 diabetic patients with normal angiograms than in controls.27 Small vessel size is strongly associated with increased risk of in-hospital mortality after CABG.28 Smaller target vessel size is also associated with increased risk of restenosis and need for repeat revascularisation after PCI.29 It has been argued that this association explains the increased procedural risk among women and smaller patients after adjustment for sex and other clinical parameters.

**Vessel involvement**

The number of diseased vessels predicts future cardiac morbidity and mortality.30 There is convincing evidence that diabetic patients have a higher incidence of multivessel disease.31–33

**Location of lesions**

Proximal segments and ostial disease are prognostically significant and are associated with a lower risk of procedural success and a higher rate of major adverse cardiac events (MACE) after PCI. It is unknown whether these lesions are found more commonly in patients with NIDDM. A higher incidence of left main stem disease is associated with NIDDM.34

**Type of lesions**

Lesions at the bifurcation of two epicardial vessels present a technical challenge to the interventionist and are associated with a higher incidence of MACE. It is unclear whether these lesions are found more commonly in diabetic patients. Similarly, total occlusions are associated with worse procedural outcome and higher rates of MACE. Some studies have observed an increase in the number of total occlusions in diabetic patients.

**Collateral circulation**

The development of a collateral coronary circulation is thought to be an important cardioprotective mechanism mediated by the endothelium in response to the development of significant myocardial ischaemia. Collateral vessel development has been shown to be impaired in DM.35 However, it is unknown what effects this has on outcomes or whether there is any relation with markers of inflammation and endothelial activation.

**Coronary artery calcification**

The onset of coronary atherosclerosis is paralleled by the development of calcification. Both insulin resistance and NIDDM are associated with increased coronary artery calcification scores as determined by electron beam computed tomography.36 37 The value of quantifying coronary artery calcification to stratify risk is controversial. However, PCI involving a calcified lesion is associated with a reduced risk of procedural success and increased risk of MACE after PCI.

**SEVERITY OF CAD IN DIABETIC PATIENTS**

Few would argue that diabetic patients tend to have a more severe and diffuse pattern of CAD, but how well has this been characterised and can we learn anything from this?

Disease severity can be usefully defined in terms of the extent of atheroma affecting the coronary tree and the number of significant stenoses.

Multivariate analysis of over 13 000 patients in CASS (coronary artery surgery study) showed a modest independent association between the presence of DM and increased severity of CAD.38 Most postmortem and angiographic studies agree that the severity of CAD is increased in patients with NIDDM.39 40 41 42 43 44 45 46 However, some studies have found no difference.36 47 48 Table 1 summarises these studies.

These varying conclusions may be the result of poor study design, low numbers of patients, and technical limitations in quantifying disease severity. Quantitative coronary angiography has been validated as an accurate means of measuring coronary severity.34 Only two studies have used quantitative coronary angiography to examine CAD severity in patients with NIDDM.49 50 Both found increased CAD severity in the diabetic groups.

IDDM has also been shown to be associated with increased disease severity.51 52 Stable angina symptoms are usually caused by the development of atherosclerotic plaque obstructing more than 70% of the lumen of the coronary vessel and are visualised easily at the time of coronary angiography. Stenosis severity is associated with increased coronary risk.53 However, plaques of only mild to moderate severity are more frequently associated with acute coronary syndromes simply because they occur much more often.46 54 This suggests that extensive and diffuse disease may be of more prognostic significance than less extensive disease with more severe stenoses. The majority of evidence supports the assertion that diabetic patients have a greater number of lesions causing significant
that this was particularly notable in female diabetic patients. Several studies reporting increased severity of disease noted greater atheroma burden. Increasing severity of CAD in diabetic patients is associated with higher mortality. Given these data one can hypothesise that disease progression is an important factor in the poorer outcomes after PCI. Therefore, one would expect that any pharmacological interventions that reduce disease severity should translate to improved outcomes.

**FACTORs IMPLICATED IN MODULATING DIABETIC CAD SEVERITY**

Table 2 outlines factors implicated in modulating the severity of CAD.

**Sex**

Several studies reporting increased severity of disease noted that this was particularly notable in female diabetic patients. The authors hypothesised that there may be a loss of the cardioprotection seen in premenopausal women. Insulin has been shown to affect the secretion of sex steroids, although it remains unclear as to whether this is of significance.

### Table 1: Summary of trials characterising the severity of coronary artery disease (CAD)

<table>
<thead>
<tr>
<th>Author and date</th>
<th>Study type</th>
<th>Inclusion criteria</th>
<th>Number of diabetic patients</th>
<th>Methods for assessing severity</th>
<th>Findings in diabetic group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IDDM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Croll 1978</td>
<td>Postmortem</td>
<td>IDDM</td>
<td>9</td>
<td>% of vessel length narrowed</td>
<td>47% had &gt;50% arterial length narrowing compared with 1% control; More multivessel disease</td>
</tr>
<tr>
<td>Valsania 1991</td>
<td>CA</td>
<td>IDDM; age and symptom matched to non-diabetic controls undergoing clinically indicated CA</td>
<td>32</td>
<td>Number of vessels with significant stenosis (&gt;70% considered significant)</td>
<td></td>
</tr>
<tr>
<td>Pajunen 2000</td>
<td>CA</td>
<td>IDDM; patients undergoing CA for suspected CAD individually matched to controls for various parameters</td>
<td>64</td>
<td>QCA to measure % of vessel involved and most severe stenosis (%); atheroma burden; Gensini score</td>
<td>More severe extensive and distal disease</td>
</tr>
<tr>
<td><strong>NIDDM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calton 1995</td>
<td>CA</td>
<td>NIDDM; individually matched</td>
<td>75</td>
<td>Coronary score</td>
<td>Higher scores; three vessel disease more common; no more diffuse disease</td>
</tr>
<tr>
<td>Hamby 1981</td>
<td>CA</td>
<td>NIDDM and IGT</td>
<td>100</td>
<td>Coronary score</td>
<td>Higher coronary scores and more three vessel disease (difference seen only in those with hypertriglyceridaemia); More three vessel disease; higher coronary score; greater effect on female diabetic patients</td>
</tr>
<tr>
<td>Natali 2000</td>
<td>CA</td>
<td>NIDDM</td>
<td>Analysis of 2253 consecutive patients</td>
<td>Coronary score</td>
<td></td>
</tr>
<tr>
<td>Pajunen 1997</td>
<td>CA</td>
<td>NIDDM; clinically indicated angiography; individually matched &quot;Adult onset&quot; DM; individually matched for age and sex</td>
<td>57</td>
<td>QCA to measure % of vessel involved and most severe stenosis (%); atheroma burden; Gensini score</td>
<td>No difference</td>
</tr>
<tr>
<td>Vigorita 1980</td>
<td>Postmortem</td>
<td>&quot;Adult onset&quot; DM; individually matched for age and sex</td>
<td>185</td>
<td>Number of coronary vessels with significant (stenosis &gt;75%) reduction in luminal area</td>
<td>More multivessel disease</td>
</tr>
<tr>
<td>Waller 1980</td>
<td>Postmortem</td>
<td>Onset of DM after age 30</td>
<td>229</td>
<td>Number of coronary vessels with significant (stenosis &gt;75%) reduction in luminal area</td>
<td>More LMS; no difference in number of stenoses between groups</td>
</tr>
<tr>
<td>Thomas 2002</td>
<td>CA</td>
<td>NIDDM; comparison with 23 non-diabetic patients; unmatched</td>
<td>59</td>
<td>QCA</td>
<td>More severe and distal disease</td>
</tr>
<tr>
<td>Waldecker 1999</td>
<td>CA</td>
<td>NIDDM presenting with acute MI; compared with 358 controls</td>
<td>46</td>
<td>Location and severity of culprit lesion; number of diseased vessels</td>
<td>More multivessel disease</td>
</tr>
<tr>
<td>Abadie 1983</td>
<td>CA</td>
<td>All DM; patients with “severe ischaemic heart disease”</td>
<td>36</td>
<td>Coronary score</td>
<td>No difference in coronary score or number of vessels involved</td>
</tr>
<tr>
<td>Cariou 2000</td>
<td>CA</td>
<td>All DM; clinically indicated CA; matched for age and sex</td>
<td>50</td>
<td>Number of significant stenoses (&gt;50%)</td>
<td>More significant stenoses; no difference in number of vessels involved or diffuse or distal disease; more LMS disease</td>
</tr>
<tr>
<td>Dorrer 1978</td>
<td>CA</td>
<td>All DM; individually matched for age, sex, and high or low risk factor status</td>
<td>37</td>
<td>Coronary score</td>
<td>Increased coronary score; no more diffuse disease.</td>
</tr>
<tr>
<td>Hochman 1988</td>
<td>Postmortem</td>
<td>All DM; specimens examined from patients with suspected CAD</td>
<td>25</td>
<td>Number of significant stenoses (&gt;75%)</td>
<td>No difference</td>
</tr>
<tr>
<td>Melidonis 1999</td>
<td>CA</td>
<td>All DM; patients with angiographically determined CAD were included and matched to controls</td>
<td>463</td>
<td>Number of diseased vessels; location of disease; luminal width</td>
<td>More three vessel disease; more RCA</td>
</tr>
<tr>
<td>Wilson 1983</td>
<td>CA</td>
<td>All DM; matched to non-diabetic controls</td>
<td>58</td>
<td>Number of major and minor lesions</td>
<td>More major stenoses; more intermediate segment disease</td>
</tr>
</tbody>
</table>

CA, coronary angiography; DM, diabetes mellitus; IDDM, insulin dependent diabetes mellitus; IGT, impaired glucose tolerance; LMS, left main stem; MI, myocardial infarction; NIDDM, non-insulin dependent diabetes mellitus; QCA, quantitative coronary angiography; RCA, right coronary artery.
Ethnicity
In certain ethnic groups mortality rates from CAD are 40% higher than those seen among whites. 37, 38 Two studies examined diabetic patients of Indian and Middle Eastern origin. They support the hypothesis of increased CAD but offer no definitive answer as to whether there is a different pattern. Calton and colleagues46 examined coronary angiograms of 75 Indian patients with NIDDM with a diagnosis of either stable or unstable angina. There was no significant difference in age or coronary risk factors between the two groups. Diabetic patients had higher coronary artery scores suggesting increased severity; however, there was no evidence of a more diffuse pattern of disease. They did more commonly have three vessel disease.

Thomas and colleagues52 examined 106 consecutive angiograms of Arab women undergoing cardiac catheterisation. They found that 82 angiograms showed evidence of CAD. Of these, 59 had NIDDM and had an increased severity of disease. There was also an increased incidence of mid and distal left anterior descending artery disease, as well as an increased number of long lesions and more distal disease. It should be noted, however, that this was a relatively small study and the patients were not individually matched.

A small study has shown no difference in CAD score between Asians and whites.54 More studies are required to determine the effect of ethnic variation on CAD severity.

Lipids
Kasaoka and colleagues55 examined the importance of lipid status and DM as independent risk factors for CAD severity and extent. They examined the coronary angiograms of 204 Japanese patients with previous myocardial infarction or angina who had angiographically proven CAD. Although both diabetes and hypercholesterolaemia were associated with more severe CAD, they found that hypercholesterolaemia had a greater influence.

The severity of angiographic CAD is related to the number of triglyceride rich lipoprotein particles and plasma Lp(a) lipoprotein concentration in patients with NIDDM.60 In another study examining patients with NIDDM, angiographic disease severity was shown to be positively associated with intermediate density lipoprotein and negatively associated with a subtype of high density lipoprotein.62 Many of the studies in the past have not taken lipid profile into account and may have been subject to confounding.

Insulin resistance
A small Japanese study has shown a correlation between a biochemical correlate of insulin resistance and CAD severity in non-diabetic patients.62 It is unknown how insulin resistance affects disease severity in patients with NIDDM.

Inflammation
Increased serum C reactive protein is associated with greater coronary risk and predicts the severity of coronary artery atherosclerosis.64 The relation between C reactive protein concentration and CAD severity remains unclear with two studies showing conflicting results.65, 66 Uprogulation of endothelial adhesion molecules such as VCAM-1 is implicated in atherogenesis. However, the association between CAD severity and soluble VCAM-1 concentration is unknown.

Hyperglycaemia
Increasing hyperglycaemia, as measured by the percentage of glycosylated haemoglobin A1c, is associated with increased severity of disease. Despite this the importance of glucose lowering interventions in reducing cardiovascular risk and its influence on outcome after PCI remains controversial.

The initial results from the UKPDS (UK prospective diabetes study) showed only minimal benefits from tight glycaemic control with respect to macrovascular disease. Each 1% reduction in haemoglobin A1c was associated with a 14% reduction in risk for myocardial infarction.67 However, relatively few macrovascular events were recorded in this study limiting its power to detect a statistical reduction. Poor glycaemic control as measured by glycosylated haemoglobin A1c concentrations at the time of PCI has been shown to be an independent predictor of restenosis in patients with DM.65 The importance of tight glycaemic control after PCI needs further investigation but is likely to be associated with an improvement in outcome. BARI 2D (bypass angioplasty revascularisation investigation) will address this issue.

In addition to more familiar risk factors, diabetic CAD may also be modulated by a number of poorly understood parameters. More studies are required to determine the relation between insulin resistance, inflammation, and CAD severity. The association between lipid lowering treatment, plaque regression, and improvement in outcome is well known. Similarly, pharmacological modulation of inflammation and insulin resistance may reduce disease severity in these patients.

CONCLUSIONS
Hyperglycaemia and insulin resistance, the two mechanisms that define NIDDM, drive the atherosclerotic process. The majority of studies confirm that NIDDM is associated with more severe CAD, which in turn is associated with a poorer prognosis.

Recent advances in our knowledge of the mechanisms underlying diabetes and atherosclerosis point to the shared importance of insulin resistance and inflammation in addition to hyperglycaemia in modulating disease severity. Reducing levels of insulin resistance and inflammation in addition to tight glycaemic control may be especially beneficial for the diabetic population undergoing PCI. The relation between these parameters requires clarification.

The pattern of diabetic CAD remains incompletely characterised. Most studies to date show a greater number of significant stenoses, more diffuse disease, and multivessel involvement. However, it is still unknown whether specific types of lesion and anatomical locations are affected more in the diabetic patients, accounting for their poorer prognosis.

Other characteristics of diabetic disease have already been elucidated such as the increase in calcified disease and decreased collateral vessel formation. These differences are implicated in the poorer prognosis after PCI. An understanding of the molecular mechanisms underlying these differences may lead to the development of pharmacological interventions to modulate them.

A more complete understanding of the anatomy of diabetic CAD and the factors that influence the pattern and severity can facilitate a more targeted approach to the development of new treatments designed to improve outcome in this growing patient population.

Authors’ affiliations
K P Morgan, A Kapur, K J Beatt, Imperial College, London, UK

REFERENCES


A 60 year old woman presented to the emergency department after four episodes of seizure. She had already experienced two repeated episodes during the past year before admission. The physical examination, including a complete neurological examination, was normal. Despite an intravenous infusion of clonazepam, another episode of seizure occurred with unresponsiveness and tonic–clonic movements followed by post-ictal confusion. The computed tomography of the head was normal. An electroencephalogram was then performed. During this recording, another episode of seizure occurred. As shown in the panel below, a polymorphic ventricular tachycardia (VT) started before any change of the electroencephalogram. The electrocerebral activity then showed an increasing amplitude followed at 14 seconds by a flattening and slowing activity (below). The polymorphic VT spontaneously resumed after 56 seconds (right panel). A long QT syndrome was diagnosed. β Blocker treatment was started and a defibrillator implanted.

This recording demonstrates that a proven seizure can be related to a spontaneous polymorphic VT. This reinforces the idea that cardiac issues should be systematically considered in patients with a diagnosis of epilepsy remaining uncertain.

O Paziaud
O Piot
N Elbaz
olivier.paziaud@libertysurf.fr

Occurrence of a spontaneous polymorphic VT during the recording of the electroencephalogram. Note that for better clarity, only six derivations of EEG are displayed, as changes in amplitude and activity were similar in 16.

doi: 10.1136/hrt.2003.028654
Spontaneous polymorphic ventricular tachycardia recorded during an electroencephalogram in a patient with apparent epilepsy
O Paziaud, O Piot and N Elbaz

*Heart* 2004 90: 738
doi: 10.1136/hrt.2003.028654

Updated information and services can be found at:
http://heart.bmj.com/content/90/7/738

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/